close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.43 +0.01 (+0.04%)
Official Closing Price Updated: 7:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Dow Jones Soars to New Record High Amidst Wave of Optimism, Signaling Robust Market Confidence
The Dow Jones Industrial Average (DJIA) recently achieved a significant milestone, surging by over 200 points to close at an unprecedented all-time record high in October 2025. This remarkable ascent... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
2 Unstoppable Health Care Giants to Buy Right Now for Less Than $1,000
These two healthcare giants are doing what they need to do to get their businesses rocking and rolling again. 
Via The Motley Fool
Topics Intellectual Property World Trade
Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030
Vertex appears to be by far the better buy right now. 
Via The Motley Fool
Topics Intellectual Property
3 Healthcare Stocks Paying the Highest Dividends of 2025
If you are looking for high yields in the healthcare sector, here are three choices. Make sure you understand the risks before you buy them. 
Via The Motley Fool
Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever.
Looking at high-yield healthcare stocks? These three stand out (but one has a slight skew to its story). 
Via The Motley Fool
Topics Government
2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Forever
Both companies are monsters in their industry and are poised to thrive. 
Via The Motley Fool
Topics Government Intellectual Property World Trade
What Occidental Petroleum’s Latest Backer Sees in Oil’s Next Chapter
What Occidental Petroleum’s Latest Backer Sees in Oil’s Next Chapter 
Via The Motley Fool
Topics Energy Regulatory Compliance
Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment
San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly... 
Via MarketMinute
Sanofi Soars as Dupixent Sales Near €5 Billion Amidst Intensifying Trump Drug Pricing Negotiations
Paris, France – October 24, 2025 – Pharmaceutical giant Sanofi (EURONEXT: SAN, NASDAQ: SNY) saw its shares climb today following the announcement of stellar third-quarter 2025 financial results,... 
Via MarketMinute
Topics Government World Trade
3 Volatile Stocks with Warning Signs
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor... 
Via StockStory
Topics Artificial Intelligence
Investment Firm Verity & Verity Loads Up With 908,000 Pfizer (PFE) Shares Worth $22.4 Million
Investment Firm Verity & Verity Loads Up With 908,000 Pfizer (PFE) Shares Worth $22.4 Million 
Via The Motley Fool
Topics Regulatory Compliance
AI Revolutionizes Drug Discovery and Personalized Medicine: A New Era of Healthcare
The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence
These S&P500 stocks are the most active in today's session
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Wednesday and discover the stocks that are dominating the trading activity and setting the pace... 
Via Chartmill
Wellgistics And DataVault Team Up To Transform Prescription Tracking
DataVault AI and Wellgistics Health are collaborating to bring blockchain technology to the US prescription drug market. 
Via Benzinga
Topics Artificial Intelligence
ARPA-H Taps Former DARPA Innovator to Ignite High-Risk, High-Reward Health Tech Revolution
In a move poised to reshape the landscape of biomedical innovation, the United States government officially appointed Dr. Renee Wegrzyn, a distinguished former official from the Defense Advanced... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
Danaher Tops Its 5% Chase Zone As One Key Division Drives Growth
Shares surged Tuesday after the medical research company beat third-quarter forecasts on the back of its bioprocessing division. 
Via Investor's Business Daily
2 Mega-Dividend Stocks With Yields As High As 7%
Dividend stocks with high yields can be great investment opportunities, but those yields can also be red flags. 
Via The Motley Fool
Topics Economy Government Intellectual Property
Mark Cuban Isn't Convinced TrumpRx Is Going To 'Change The Game' But He's Giving Them 'Credit For Trying'
Billionaire entrepreneur Mark Cuban offered rare praise for the Trump administration's push to lower prescription drug costs, calling its TrumpRx initiative "a good start," while still acknowledging... 
Via Benzinga
Topics Government
2 Large-Cap Stocks with Exciting Potential and 1 We Avoid
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an... 
Via StockStory
Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche
The company took on Roche's Xolair in a 16-week study of patients with a chronic hives disorder. 
Via Investor's Business Daily
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
2 High-Yield Dividend Stocks Too Cheap to Ignore
They are both yielding above 5%. 
Via The Motley Fool
Topics Intellectual Property World Trade
Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients
Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with bladder cancer. 
Via Investor's Business Daily
Invo Fertility Stock Is Plunging After White House Announcement
INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible. 
Via Benzinga
Why Eli Lilly (LLY) Stock Is Down Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.5% in the afternoon session after political comments introduced significant uncertainty regarding the future pricing of the company’s... 
Via StockStory
Topics Economy Government
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment
NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to daily oral medication. 
Via Benzinga
QSM Asset Management Dumps 36,000 Whirlpool (WHR) Shares in Q3 2025
Via The Motley Fool
Topics Regulatory Compliance
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer. 
Via Benzinga
Topics Government
Eli Lilly Makes A Bold Claim For Its Biggest Cancer Drug
Eli Lilly said Friday a combo using Verzenio cut the risk of death by nearly 16% over two years for breast cancer patients. 
Via Investor's Business Daily
ASSET PLANNING Exits Full Stake in Pfizer Worth $2.7 Million
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today